The other half of the story

The six major Lyme coinfections

Borrelia rarely travels alone. These six tick-borne and stealth pathogens drive much of the chronic, multisystem illness attributed to Lyme — and each has its own research trail and its own country-by-country treatment landscape.

Conditions linked to Babesia in peer-reviewed research

Every card links to a PubMed paper documenting the association.

Treatment atlas

How Babesia is treated across 5 countries

First-line acute protocols, chronic / integrative approaches, and clinical notes for the United States, United Kingdom, Germany, Switzerland and Sweden.

CountryAcute / first-lineChronic / integrativeNotes
🇺🇸United States
Atovaquone + azithromycin 7–10 days (CDC); clindamycin + quinine for severe.ILADS: atovaquone + azithro 3–6 months; add cryptolepis, artemisinin, methylene blue.Exchange transfusion for severe parasitemia >10%.
🇬🇧United Kingdom
Rarely diagnosed; UKHSA refers to specialist tropical disease unit.Not recognized on NHS — patients self-treat or travel to DE/CH.Babesia divergens (Europe) is more severe than US strains.
🇩🇪Germany
Atovaquone + azithromycin per BCA / Klinik St. Georg protocols.Pulsed combination + whole-body hyperthermia (Babesia is heat-sensitive).Hyperthermia at 41.6°C considered highly effective for Babesia.
🇨🇭Switzerland
Atovaquone + azithro per acute infectious disease guidance.Paracelsus / Swiss Mountain: hyperthermia, ozone, IV artemisinin, methylene blue.Limited public-system recognition; integrative clinics lead.
🇳🇱Netherlands
Rarely tested or recognized in public health.Patients travel to Germany/Belgium or use herbal protocols.Access to Babesia testing is extremely limited via GP.
🇸🇪Sweden
Atovaquone + azithromycin when diagnosed (rare).No chronic treatment in public system; referral abroad common.Awareness low; Folkhälsomyndigheten data sparse.